文献速递中医儿科中药与中成药合理使用

银胡感冒散治疗儿童急性上呼吸道感染(风热证)的前瞻性真实世界队列研究

Treatment of children with acute upper respiratory tract infection (wind-heat pattern) with Yin Hu Gan Mao San: a prospective real-world cohort study.
PubMed 文献 · Front Pharmacol · 2026-07-02

本研究为前瞻性真实世界队列研究,纳入23家医院999例急性上呼吸道感染风热证患儿,暴露组671例接受银胡感冒散治疗,非暴露组328例未接受银胡感冒散或其他中药,采用倾向性评分匹配平衡基线特征。结果显示银胡感冒散组第3、5、7天恢复率显著更高,中位恢复时间和体温正常时间更短,不良反应发生率低(1.51%),仅为轻微自限性局部皮肤反应。

要点

  • 银胡感冒散可提高患儿第3、5、7天临床恢复率并缩短恢复时间。
  • 银胡感冒散组体温正常时间中位数为1.0天,较对照组2.0天显著缩短。
  • 不良反应发生率低(1.51%),均为轻微自限性局部皮肤反应。

核心结论

  • 银胡感冒散与儿童急性上呼吸道感染(风热证)更快的临床恢复和症状缓解相关,且未见显著安全性问题。
  • 作为单药治疗,银胡感冒散优于单纯化学药治疗;联合用药时也可加速临床症状缓解和恢复。

研究设计与样本

  • 前瞻性真实世界队列研究,纳入2022年5月至2023年6月23家医院的999例急性上呼吸道感染患儿。
  • 暴露组671例接受银胡感冒散治疗,非暴露组328例未接受银胡感冒散或其他中药,采用倾向性评分匹配平衡基线特征。

主要发现

  • 倾向性评分匹配后,银胡感冒散组第3天恢复率52.64% vs 36.09%,第5天81.00% vs 68.81%,第7天94.72% vs 87.64%(均P < 0.0001)。
  • 银胡感冒散组中位恢复时间3.0天 vs 4.0天,体温正常时间1.0天 vs 2.0天(均P < 0.0001)。
  • 银胡感冒散组各单项症状缓解率均持续高于对照组。
  • 不良反应发生率为1.51%,仅为轻微自限性局部皮肤反应。

临床怎么用

  • 对于儿童急性上呼吸道感染风热证,可考虑使用银胡感冒散以加快临床恢复和症状缓解。
  • 使用银胡感冒散时需关注局部皮肤反应,但多为轻微且自限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Yin Hu Gan Mao San (YHGMS) is a traditional Chinese herbal preparation derived from Yin Qiao San, used for topical application to treat wind-heat colds. This study aims to evaluate the clinical efficacy and safety of YHGMS in children with acute upper respiratory tract infection (AURTI) of wind-heat pattern. METHODS: This prospective, real-world cohort study enrolled 999 children with AURTI from 23 hospitals from May 2022 to June 2023. Participants were naturally divided into an exposed group (n = 671) that received YHGMS and a non-exposed group (n = 328) that did not receive YHGMS or any other traditional Chinese medicine. Propensity score matching was used to balance baseline characteristics. Primary outcomes included clinical recovery rate and time to recovery. Secondary outcomes included time to normal temperature, symptom resolution rates, and safety profile. RESULTS: After propensity score matching, the YHGMS group demonstrated significantly higher recovery rates on day 3 (52.64% vs. 36.09%), day 5 (81.00% vs. 68.81%), and day 7 (94.72% vs. 87.64%) (all P < 0.0001). Median recovery time (3.0 vs. 4.0 days) and time to normal temperature (1.0 vs. 2.0 days) were significantly shorter in the YHGMS group (both P < 0.0001). Resolution rates of individual symptoms were consistently higher in the YHGMS group. The incidence of adverse reactions was low (1.51%), comprising only mild, self-limiting local skin reactions. CONCLUSION: YHGMS was associated with faster clinical recovery and symptom resolution in children with AURTI (wind-heat pattern), without significant safety concerns. As monotherapy, YHGMS showed better outcomes than chemical medicine alone; in combination, it also accelerated resolution of clinical symptoms and recovery.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Li J, Huang T, Ning L, et al. Treatment of children with acute upper respiratory tract infection (wind-heat pattern) with Yin Hu Gan Mao San: a prospective real-world cohort study. Front Pharmacol. 2026. PMID: 42466003. doi:10.3389/fphar.2026.1838314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。